WEBULL
WebtradeDownload

HUTCHMED (China) (AIM:HCM) FDA Filing Puts Its Undervalued Narrative Back In Focus

Simply Wall St · 2d ago

AstraZeneca’s FDA filing for the ORPATHYS plus TAGRISSO lung cancer combination puts HUTCHMED (China) (AIM:HCM) at a key regulatory moment, supported by SAFFRON Phase III survival data and a clean safety readout.

The FDA filing lands against a backdrop of improving share price momentum for HUTCHMED (China). The stock is at £2.15 after a 24.28% 90 day share price return and an 11.98% 30 day share price gain, even though the 1 year total shareholder return is still down 7.33% and the 5 year total shareholder return has declined 54.45%. This signals that recent optimism around events like the ORPATHYS and TAGRISSO combination is building on a much weaker long term experience for holders.

Scan how HUTCHMED (China) compares with other oncology-focused players by reviewing a curated set of 7 healthcare AI stocks aligned with similar treatment and precision-medicine themes.

After a sharp rebound in HUTCHMED (China) shares and a fresh FDA filing on the table, does the current setup still reward new risk takers or has most of the upside already been priced in?

Most Popular Narrative: 38% Undervalued

The prevailing narrative puts HUTCHMED (China) on a fair value of £3.46 against a last close of £2.15, which presents the current optimism as a valuation gap rather than pure hype.

Expansion of approved indications and upcoming NDA submissions for key oncology products (savolitinib and fruquintinib) are expected to support higher revenue growth, supported by demand from an aging population and increased chronic disease prevalence in China and globally.

Launches and global expansion of FRUZAQLA, including growth outside China (notably in Japan and in anticipation of further global rollouts), position the company to participate in rising healthcare spending and broader reimbursement coverage, which may support top-line growth.

See why 5 investors see HUTCHMED (China) as 38% undervalued.

Result: Fair Value of £3.46 (UNDERVALUED)

Still, the HUTCHMED (China) story can change quickly if key trials disappoint or if changes in China’s pricing and regulatory environment hit oncology demand harder than analysts model.

Find out about the key risks to this HUTCHMED (China) narrative.

Another View: HUTCHMED (China) Looks Expensive On Earnings

Look past the fair value estimate and the story changes. On a P/E of 138x, HUTCHMED (China) trades at a big premium to both peers at 18.8x and its own fair ratio of 29.1x, which points to rich expectations. If sentiment cools, how much valuation air could come out of that multiple?

Our earnings based check paints a very different picture of the current price level, and the numbers behind it are worth understanding in more detail. See what the numbers say about this price — find out in our valuation breakdown.

AIM:HCM P/E Ratio as at Oct 2026
AIM:HCM P/E Ratio as at Oct 2026

Next Steps

Mixed signals around HUTCHMED (China) can easily pull you in either direction, so move quickly, review the underlying data yourself, and decide where you land with 2 key rewards and 2 important warning signs

Looking for more HUTCHMED (China) style investment ideas?

If HUTCHMED (China) has caught your eye, do not stop here. Fresh ideas from other corners of the market can help inform your overall portfolio decisions.

Use the Simply Wall Street Screener to quickly surface three very different sets of stocks that could complement your current watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.